OSTEOPORE LIMITED — Director's Dealing 2024

May 14, 2024

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Osteopore Limited ABN 65 630 538 957

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

We (the entity) give ASX the following the director for the purposes of section	information under listing rule 3.19A.2 and as agent for 205G of the Corporations Act.
Name of Director	Mark Leong
Date of last notice	6 March 2024

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mark Leong Mark Leong is a Director of Avalon Partners Pte Ltd.
Date of change		8 May 2024
No. of securities held prior to change		Mark Leong 12,500 Fully paid ordinary shares 2,500 Listed Options Mark Leong 66,667 performance rights (Tranche A) 100,000 performance rights (Tranche B) 116,667 performance rights (Tranche C) 150,000 performance rights (Tranche D) 183,334 performance rights (Tranche E)

Appendix 3Y Change of Director’s Interest Notice

Class		1. Fully paid ordinary shares 2. Unlisted free-attaching options exercisable at $0.0387 each expiring on 2 April 2026
Number acquired		1. 125,000 fully paid ordinary shares 2. 25,000 unlisted free-attaching options exercisable at $0.0387 each expiring on 2 April 2026
Number disposed		Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		1. A$3,625 2. Nil
No. of securities held after change		Mark Leong 137,500 Fully paid ordinary shares 2,500 Listed Options 25,000 unlisted free-attaching options exercisable at $0.0387 each expiring on 2 April 2026 Mark Leong 66,667 performance rights (Tranche A) 100,000 performance rights (Tranche B) 116,667 performance rights (Tranche C) 150,000 performance rights (Tranche D) 183,334 performance rights (Tranche E)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		Participation in renounceable entitlement offer

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 2

3476-8750-0327, v. 1

Appendix 3Y Change of Director’s Interest Notice

Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3

3476-8750-0327, v. 1

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Osteopore Limited ABN 65 630 538 957

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

We (the entity) give ASX the following the director for the purposes of section	information under listing rule 3.19A.2 and as agent for 205G of the Corporations Act.
Name of Director	Teoh Swee Hin
Date of last notice	6 March 2024

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest		Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		BNP Paribas Noms Pty Ltd as custodian for Professor Teoh Swee Hin
Date of change		8 May 2024
No. of securities held prior to change		Direct: Teoh Swee Hin 6,667 Performance Rights (Tranche A) 10,000 Performance Rights (Tranche B) 11,667 Performance Rights (Tranche C) 15,000 Performance Rights (Tranche D) 18,334 Performance Rights (Tranche E) Indirect: BNP Paribas Noms Pty Ltd R’Miers> as custodian for Professor Teoh Swee Hin 594,192 Fully paid ordinary shares 118,838 Listed options

Appendix 3Y Change of Director’s Interest Notice

Class		1. Fully paid ordinary shares 2. Unlisted free-attaching options exercisable at $0.0387 each expiring on 2 April 2026
Number acquired		1. 584,897 fully paid ordinary shares 2. 116,979 unlisted free-attaching options exercisable at $0.0387 each expiring on 2 April 2026
Number disposed		Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		1. A$16,962 2. Nil
No. of securities held after change		Direct: Teoh Swee Hin 6,667 Performance Rights (Tranche A) 10,000 Performance Rights (Tranche B) 11,667 Performance Rights (Tranche C) 15,000 Performance Rights (Tranche D) 18,334 Performance Rights (Tranche E) Indirect: BNP Paribas Noms Pty Ltd R’Miers> as custodian for Professor Teoh Swee Hin 1,179,089 Fully paid ordinary shares 118,838 Listed options 116,979 unlisted free-attaching options exercisable at $0.0387 each expiring on 2 April 2026
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		Participation in renounceable entitlement offer

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 2

3445-6615-1719, v. 1

Appendix 3Y Change of Director’s Interest Notice

Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3

3445-6615-1719, v. 1